![Ayman Mohamed](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ayman Mohamed
Direttore Tecnico/Scientifico/R&S presso PRECIPIO, INC.
Patrimonio netto: 1 089 $ in data 31/05/2024
Profilo
Ayman A.
Mohamed is the founder of Precipio Diagnostics LLC.
He is currently working as the Chief Technology Officer at Precipio, Inc. Previously, he worked as the Vice President-Research & Development at Transgenomic, Inc. Dr. Mohamed completed his graduate and doctorate degrees at Alexandria University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
PRECIPIO, INC.
0.01% | 19/04/2024 | 189 ( 0.01% ) | 1 089 $ | 31/05/2024 |
Posizioni attive di Ayman Mohamed
Società | Posizione | Inizio |
---|---|---|
PRECIPIO, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2017 |
Precedenti posizioni note di Ayman Mohamed
Società | Posizione | Fine |
---|---|---|
Transgenomic, Inc.
![]() Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Direttore Tecnico/Scientifico/R&S | - |
Precipio Diagnostics LLC
![]() Precipio Diagnostics LLC Medical/Nursing ServicesHealth Services Precipio Diagnostics LLC operates as a cancer diagnostics reference laboratory. It offers its customers community oncologists and hospitals access to academic institutions and has combined academic-level excellence with the sales and marketing expertise, the proper operational processes and the necessary service level standards required to deliver proper support. The company was founded by Ilan Danieli in 2011 and is headquartered in New Haven, CT. | Fondatore | - |
Formazione di Ayman Mohamed
Alexandria University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
PRECIPIO, INC. | Health Services |
Aziende private | 2 |
---|---|
Precipio Diagnostics LLC
![]() Precipio Diagnostics LLC Medical/Nursing ServicesHealth Services Precipio Diagnostics LLC operates as a cancer diagnostics reference laboratory. It offers its customers community oncologists and hospitals access to academic institutions and has combined academic-level excellence with the sales and marketing expertise, the proper operational processes and the necessary service level standards required to deliver proper support. The company was founded by Ilan Danieli in 2011 and is headquartered in New Haven, CT. | Health Services |
Transgenomic, Inc.
![]() Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Health Technology |
- Borsa valori
- Insiders
- Ayman Mohamed